Compare Stocks → Did You Get Your Free Bitcoin Yet? (From Crypto Swap Profits) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison OTCMKTS:ASPCFNASDAQ:CLSNNASDAQ:PPBTNASDAQ:VCNX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASPCFAcerus Pharmaceuticals$0.22$0.22$0.22▼$8.16$1.70M0.691,500 shsN/ACLSNImunon$2.22$1.80▼$15.75$13.91M2.27150,471 shs711 shsPPBTPurple Biotech$0.67+9.8%$0.72$0.53▼$2.16$16.91M0.97114,926 shs98,128 shsVCNXVaccinex$7.41-0.5%$8.64$7.16▼$100.80$6.60M0.7610,810 shs18,505 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASPCFAcerus Pharmaceuticals0.00%0.00%0.00%0.00%0.00%CLSNImunon0.00%0.00%0.00%0.00%0.00%PPBTPurple Biotech+8.06%-0.30%-0.09%-14.10%-62.57%VCNXVaccinex-1.20%-10.72%-12.93%-20.38%-91.45%Major Elon Musk Crypto Leak Revealed (Ad)Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.Click here now to get your copy.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationASPCFAcerus PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACLSNImunonN/AN/AN/AN/AN/AN/AN/AN/APPBTPurple Biotech2.4762 of 5 stars3.55.00.00.02.40.00.6VCNXVaccinexN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASPCFAcerus PharmaceuticalsN/AN/AN/AN/ACLSNImunonN/AN/AN/AN/APPBTPurple Biotech3.00Buy$9.001,243.28% UpsideVCNXVaccinexN/AN/AN/AN/ACurrent Analyst RatingsLatest CLSN, VCNX, PPBT, and ASPCF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/5/2024PPBTPurple BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.002/27/2024PPBTPurple BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00(Data available from 3/29/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASPCFAcerus Pharmaceuticals$2.12M0.80N/AN/A($3.38) per share-0.07CLSNImunon$500K0.00N/AN/A$9.66 per share0.00PPBTPurple BiotechN/AN/AN/AN/A$1.36 per shareN/AVCNXVaccinex$280K23.55N/AN/A$21.86 per share0.34Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASPCFAcerus Pharmaceuticals-$33.82M-$3.57N/A∞N/A-924.33%N/A-74.62%N/ACLSNImunon-$20.77MN/A0.00N/AN/A-5,229.80%-50.18%-36.94%N/APPBTPurple Biotech-$19.88M-$0.92N/AN/AN/AN/A-57.40%-49.02%5/21/2024 (Estimated)VCNXVaccinex-$19.82M-$84.56N/A∞N/AN/A-2,667.31%-475.55%4/1/2024 (Estimated)Latest CLSN, VCNX, PPBT, and ASPCF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/5/2024Q4 2023PPBTPurple Biotech-$0.17-$0.32-$0.15-$0.45N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASPCFAcerus PharmaceuticalsN/AN/AN/AN/AN/ACLSNImunonN/AN/AN/AN/AN/APPBTPurple BiotechN/AN/AN/AN/AN/AVCNXVaccinexN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASPCFAcerus PharmaceuticalsN/A0.670.34CLSNImunon0.136.526.52PPBTPurple BiotechN/A2.202.20VCNXVaccinexN/A0.350.35OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASPCFAcerus PharmaceuticalsN/ACLSNImunon12.97%PPBTPurple Biotech9.64%VCNXVaccinex50.11%Insider OwnershipCompanyInsider OwnershipASPCFAcerus PharmaceuticalsN/ACLSNImunon4.66%PPBTPurple Biotech2.98%VCNXVaccinex51.30%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableASPCFAcerus Pharmaceuticals147.71 millionN/ANot OptionableCLSNImunon277.10 million6.77 millionOptionablePPBTPurple Biotech2025.24 million24.49 millionOptionableVCNXVaccinex38890,000434,000OptionableCLSN, VCNX, PPBT, and ASPCF HeadlinesSourceHeadlineShort Interest in Vaccinex, Inc. (NASDAQ:VCNX) Declines By 40.5%americanbankingnews.com - March 28 at 1:54 AMVaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rulesglobenewswire.com - March 27 at 8:30 AMVaccinex CFO Scott Royer to retire, Jill Sanchez steps ininvesting.com - March 6 at 7:15 PMVaccinex Inc VCNXmorningstar.com - March 2 at 3:46 PMVaccinex, Inc.: Vaccinex Announces Multiple New Agreements for Access to ActivMAb Antigen Virus Technologyfinanznachrichten.de - February 21 at 9:42 AMVaccinex Enters Antibody Discovery Agreements Incorporating ActivMAb Drug Discovery Platformmarkets.businessinsider.com - February 21 at 9:42 AMVaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technologyfinance.yahoo.com - February 21 at 9:42 AMVaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technologyglobenewswire.com - February 21 at 8:00 AMVaccinex Announces 1-For-14 Reverse Stock Splitmarkets.businessinsider.com - February 15 at 4:28 PMWhy Vaccinex (VCNX) Stock Is Trading Lowermsn.com - February 15 at 4:28 PMVaccinex, Inc. Announces Reverse Stock Splitglobenewswire.com - February 15 at 8:00 AMSteven Cohen's Point72 Asset Management Acquires New Stake in Vaccinex Incfinance.yahoo.com - February 12 at 2:49 PMVaccinex Inc Secures $3.7M in Private Placement Dealmsn.com - February 8 at 10:26 AMWhy Vaccinex (VCNX) Stock Is Popping Offmsn.com - February 7 at 2:45 PMVaccinex Announces Pricing of $3.7 Million PIPE Financingmarkets.businessinsider.com - February 7 at 9:45 AMA phase 1b/2 trial of pepinemab and avelumab as second line therapy for patients with metastatic pancreatic adenocarcinoma.ascopubs.org - January 30 at 7:55 PMNasdaq Grants Vaccinex Extension Until March 4, 2024 to Regain Compliance with Listing Rulefinance.yahoo.com - December 4 at 8:50 AMVaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate Updatefinance.yahoo.com - November 13 at 9:59 AMVaccinex Reports Clinical Benefit in Interim Analyses from two Phase 2 Studies of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meetingfinance.yahoo.com - October 31 at 11:18 AMVaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation in Neurodegenerative Diseasesfinance.yahoo.com - October 26 at 9:40 AMUnderstanding the Risks of Investing in Vaccinex Inc (VCNX)knoxdaily.com - October 17 at 9:03 PMVaccinex Inc [NASDAQ: VCNX] Sees Decrease in Stock Valueknoxdaily.com - October 6 at 7:10 PMWhy Is Vaccinex (VCNX) Stock Up 26% Today?markets.businessinsider.com - October 6 at 8:58 AMVaccinex, Inc.: Vaccinex Announces Pricing of $9.6 Million Public Offeringfinanznachrichten.de - September 29 at 11:01 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAcerus PharmaceuticalsOTCMKTS:ASPCFAcerus Pharmaceuticals Corp. is a pharmaceutical company. The firm is focused on the commercialization and development of prescription products that improve patient experience, with a focus in the field of men's health. It focuses on therapeutics for urology, andrology, and endocrinology. Its products include Estrace and Natesto. The company was founded by Bruce D. Brydon, Rolf K. Reininghaus and Mark L. Thompson on September 9, 2008 and is headquartered in Mississauga, Canada.ImunonNASDAQ:CLSNCelsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.Purple BiotechNASDAQ:PPBTPurple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company for the Phase 2 clinical trials to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy; and Mor Research Applications. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.VaccinexNASDAQ:VCNXVaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. Its Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. It has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. The company was incorporated in 2001 and is headquartered in Rochester, New York. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.